View of MELANOSIS SECONDARY TO PEGYLATED LIPOSOMAL DOXORUBICIN FOR OVARIAN CANCER TREATMENT: AN UNCOMMON EXPRESSION OF SKIN SIDE EFFECTS

Return to Article Details MELANOSIS SECONDARY TO PEGYLATED LIPOSOMAL DOXORUBICIN FOR OVARIAN CANCER TREATMENT: AN UNCOMMON EXPRESSION OF SKIN SIDE EFFECTS Download Download PDF